Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DORISS: Dolutegravir + Rilpivirine Switch Study
NCT02069834Phase 3Withdrawn
- Sponsor
- CHU de Nantes
- Start
- May 2014
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dolutegravir, rilpivirine in human immunodeficiency virus infection (HIV), sponsored by CHU de Nantes. Planned start May 2014; status: withdrawn.
02
Drugs
dolutegravirrilpivirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02069834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02069834.